Crescendo Bioscience, Inc. (NASDAQ:MYGN)

CAPS Rating: 3 out of 5

Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.


Player Avatar searchsoon (< 20) Submitted: 6/10/2010 9:21:31 AM : Outperform Start Price: $17.99 MYGN Score: -7.96

MYGN must invest in new areas otherwise its stock declines. others are moving: examination &quot;early Cdt for lung cancer and a new blood test for cancerof Oncimmune for exemple. Without innovation only speculation made by the robbers of the people.Does MYGN want to accept the challenge?

Member Avatar thousandsfalls (< 20) Submitted: 6/14/2010 12:31:18 PM
Recs: 0

Myriad Genetics Earnings In Retrospect: Down 26.95% In Last 38 Days

Featured Broker Partners